The development of ADAM10 endocytosis inhibitors for the treatment of Alzheimer’s disease

The development of new therapeutic avenues that target the early stages of Alzheimer’s disease (AD) is urgently necessary. A disintegrin and metalloproteinase domain 10 (ADAM10) is a sheddase that is involved in dendritic spine shaping and limits the generation of amyloid-β. ADAM10 endocytosis incre...

Descripción completa

Detalles Bibliográficos
Autores principales: Musardo, Stefano, Therin, Sebastien, Pelucchi, Silvia, D’Andrea, Laura, Stringhi, Ramona, Ribeiro, Ana, Manca, Annalisa, Balducci, Claudia, Pagano, Jessica, Sala, Carlo, Verpelli, Chiara, Grieco, Valeria, Edefonti, Valeria, Forloni, Gianluigi, Gardoni, Fabrizio, Meli, Giovanni, Di Marino, Daniele, Di Luca, Monica, Marcello, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263258/
https://www.ncbi.nlm.nih.gov/pubmed/35390543
http://dx.doi.org/10.1016/j.ymthe.2022.03.024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9263258/
https://www.ncbi.nlm.nih.gov/pubmed/35390543
http://dx.doi.org/10.1016/j.ymthe.2022.03.024

Ejemplares similares